Clinical Trial Update: A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and safety of LAG525 with spartalizumab, with or without carboplatin, in advanced triple-negative breast cancer; study complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• LAG525
• Spartalizumab (spartalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-05-13